IPO Market Enters Fourth Quarter with the Wind at its Back The US IPO market saw 29 IPOs raise $4.1 billion in the third quarter, a drop from the prior year period. Small-cap health care companies, mostly biotechs, made up almost half of all...read more
Two IPOs raised a combined $574 million this past week and notched modest gains. Pigments supplier Venator Materials raised $454 million and ultra-rare bone disease biotech Clementia Pharmaceuticals raised $120 million. July 2017 was the ...read more
Two health care companies priced their delayed IPOs this week to raise a combined $132 million. In other IPO news, Snap broke below its issue price and the pipeline saw new filings from a high-growth retailer and a fracker, along with an energy withdrawal. Six...read more
Akcea Therapeutics, a late-stage biotech developing therapies for rare lipid disorders, raised $125 million by offering 15.6 million shares at $8, below the range of $12 to $14. It added 6.0 million shares to the offering to keep the deal size unchanged. Akcea...read more
Renaissance Capital's 3Q17 US IPO Market Review
IPO Market Enters Fourth Quarter with the Wind at its Back The US IPO market saw 29 IPOs raise $4.1 billion in the third quarter, a drop from the prior year period. Small-cap health care companies, mostly biotechs, made up almost half of all...read more
US IPO Weekly Recap: Two IPOs start off the annual August lull
Two IPOs raised a combined $574 million this past week and notched modest gains. Pigments supplier Venator Materials raised $454 million and ultra-rare bone disease biotech Clementia Pharmaceuticals raised $120 million. July 2017 was the ...read more
US IPO Weekly Recap: 2 health care companies price, Snap breaks
Two health care companies priced their delayed IPOs this week to raise a combined $132 million. In other IPO news, Snap broke below its issue price and the pipeline saw new filings from a high-growth retailer and a fracker, along with an energy withdrawal. Six...read more
Lipid biotech Akcea Therapeutics prices upsized $125 million IPO at $8, below the range
Akcea Therapeutics, a late-stage biotech developing therapies for rare lipid disorders, raised $125 million by offering 15.6 million shares at $8, below the range of $12 to $14. It added 6.0 million shares to the offering to keep the deal size unchanged. Akcea...read more